Fernando Herranz (@fherranz.bsky.social)

For patients with severe Leukocyte Adhesion Deficiency Type I (LAD-I), treatment options have been limited. A new gene therapy may offer hope through the FDA’s accelerated approval pathway… | FDA For patients with severe Leukocyte Adhesion Deficiency Type I (LAD-I), treatment options have been limited. A new gene therapy may offer hope through the FDA’s accelerated approval pathway. https://ln... https://www.linkedin.com/posts/fda_for-patients-with-severe-leukocyte-adhesion-ugcPost-7443067620632891392-fQMu?utm_medium=ios_app&rcm=ACoAAAXLtBQBTOp5uzKX86ZlVFdRiekHx8Fmr-M&utm_source=social_share_send&utm_campaign=copy_link